53 completed, 26 recruiting, 25 terminated, 23 active not recruiting. 158 Phase 2, 53 Phase 1, 1 Phase 3.
Follow pomalidomide: new trials by email Literature Review of pomalidomide trials Research Report on pomalidomide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 80 | 2027-05-22 | 2026-11-04 |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma Cevostamab, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 2 | Recruiting | Hoffmann-La Roche | 45 | 2026-11-03 | 2026-11-05 |
| Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma. Belantamab Mafodotin, Pomalidomide, Dexamethasone - Relapsed / Refractory Multiple Myeloma | Phase 2 | Not yet recruiting | Polish Myeloma Consortium | 228 | 2026-10-01 | 2026-08-06 |
| Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma. Teclistamab (Tec) and Pomalidomide (Pom) - Multiple Myeloma Progression | Phase 2 | Not yet recruiting | Odense University Hospital | 50 | 2026-09-01 | 2026-08-11 |
| Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL hypofractionated radiotherapy plus GM-CSF, pomalidomide and glofitamab - DLBCL - Diffuse Large B Cell Lymphoma, PCNSL (Primary CNS Lymphoma) | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 53 | 2026-07-25 | 2026-08-06 |
| QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms QLS4131, QL2109, Pomalidomide - Malignant Plasma Cell Neoplasms | Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 162 | 2026-06-01 | 2026-05-01 |
| A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) Belantamab mafodotin, Dexamethasone, Pomalidomide - Multiple Myeloma | Phase 2 | Recruiting | GlaxoSmithKline | 200 | 2026-04-15 | 2026-08-25 |
| Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma Pomalidomide, PD-1 / PD-L1 monoclonal antibody, XPO1 inhibitor - Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Beijing Tongren Hospital | 43 | 2026-04-01 | 2026-04-15 |
| Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Inobrodib, Pomalidomide, Dexamethasone - Multiple Myeloma Refractory, Multiple Myeloma in Relapse | Phase 2 | Recruiting | CellCentric Ltd. | 100 | 2026-01-22 | 2026-09-21 |
| Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma QLS32015, Pomalidomide, Dexamethasone - Relapsed or Refractory Multiple Myeloma | Phase 2 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 160 | 2025-09-12 | 2026-06-08 |
| A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) Surzetoclax, Daratumumab, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | AbbVie | 325 | 2025-07-23 | 2026-10-27 |
| A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma F182112+P, F182112+CD38 - Relapsed or Refractory Multiple Myeloma | Phase 2 | Recruiting | Shandong New Time Pharmaceutical Co., LTD | 90 | 2025-07-02 | 2025-12-31 |
| A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations Etentamig, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | AbbVie | 602 | 2025-06-30 | 2026-10-19 |
| Pomalidomide as an Immune-enhancing Agent for the Control of HIV Pomalidomide 2 mg, Placebo, Aspirin 75 mg - HIV-1 Infection | Phase 1 / Phase 2 | Active not recruiting | University of Aarhus | 32 | 2025-05-13 | 2026-05-07 |
| KPD Consolidation After ASCT in NDMM Patients KPD (carfilzomib, pomalidomide, and dexamethasone) consolidation - Multiple Myeloma, Newly Diagnosed | Phase 2 / Phase 3 | Recruiting | Peking University People's Hospital | 202 | 2025-03-01 | 2025-03-17 |
| A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma Pomalidomide, Rituximab, Methotrexate - PCNSL | Phase 1 / Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 43 | 2024-08-31 | 2024-08-15 |
| Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma Isatuximab, Belantamab mafodotin, Pomalidomide - Relapsed Cancer, Refractory Multiple Myeloma | Phase 2 | Recruiting | Massachusetts General Hospital | 50 | 2024-05-31 | 2026-01-14 |
| Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis Bortezomib, Pomalidomide, Dexamethasone - Systemic Amyloidosis | Phase 2 | Recruiting | Jin Lu, MD | 40 | 2024-05-06 | 2024-12-30 |
| Marizomib Central Nervous System (CNS) Marizomib, Pomalidomide, Dexamethasone - Multiple Myeloma, Multiple Myeloma in Relapse | Phase 2 | Withdrawn | Dana-Farber Cancer Institute | 2024-03-01 | 2024-07-16 |
Showing 20 of 158. Sign in to see all of them.
Multiple Myeloma (110) · Recurrence (28) · Neoplasms (9) · Neoplasms, Plasma Cell (9) · Immunoglobulin Light-chain Amyloidosis (7) · Blood Protein Disorders (3) · Hematologic Diseases (3) · Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma, Non-Hodgkin (3) · Myeloproliferative Disorders (3) · Amyloidosis (2) · Chromosome 17 deletion (2) · Graft vs Host Disease (2) · Hematologic Neoplasms (2) · Leukemia, Myeloid, Acute (2)
Celgene (9) · Mayo Clinic (9) · National Cancer Institute (NCI) (7) · Oncotherapeutics (5) · Weill Medical College of Cornell University (5) · Bristol-Myers Squibb (4) · GlaxoSmithKline (4) · AbbVie (3) · Celgene Corporation (3) · Canadian Myeloma Research Group (2) · CellCentric Ltd. (2) · City of Hope Medical Center (2) · Dana-Farber Cancer Institute (2) · Emory University (2) · Fondazione EMN Italy Onlus (2)
United States (104) · France (20) · China (19) · Italy (19) · Spain (19) · Canada (18) · Germany (18) · United Kingdom (16) · Australia (14) · Greece (13) · Japan (10) · South Korea (9) · Poland (8) · Sweden (7) · Brazil (6)
James R Berenson, MD (5) · Andrew J Yee, MD (2) · Evangelos Terpos, Prof (2) · Jin Lu, M.D. (2) · Noa Biran, MD (2) · Ruben Niesvizky, MD (2) · Shaji Kumar (2) · Abderrahim Fandi, MD (1) · Ajai Chari, MD (1)
PMID 40226119, PMID 10564685, PMID 15902208, PMID 15958804, PMID 17975015, PMID 18032762, PMID 18032763, PMID 19901123, PMID 21690557, PMID 22493299, PMID 23243282, PMID 23319574, PMID 23370364, PMID 23890523, PMID 23954889, PMID 24421329, PMID 25047979, PMID 25482239, PMID 25575538, PMID 25869284, PMID 26384354, PMID 26932802, PMID 27096106, PMID 27267105, PMID 27269947, PMID 27381904, PMID 27774990, PMID 27863194, PMID 28130212, PMID 28461396, PMID 28684537, PMID 30352784, PMID 30403938, PMID 30792190, PMID 31588567, PMID 32171061, PMID 32501528, PMID 32928795, PMID 33025730, PMID 33682447, PMID 33730360, PMID 34168987, PMID 34551886, PMID 34559902, PMID 34818965, PMID 34862247, PMID 35027656, PMID 35075109, PMID 35133221, PMID 35960908
2023 (5), P30CA015083 (5), 2016 (3), 2025 (3), 2009 (2), 2014 (2), P30CA138292 (2), U10CA180820 (2), UM1CA121947 (2), 2017 (1), 2018 (1), 2019 (1), P30CA046934 (1), U10CA031946 (1), UM1CA186712 (1)